Cargando…

Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody

Although chimeric antigen receptor (CAR) T cell immunotherapy has shown promising significance in B cell malignancies, success against T cell malignancies remains unsatisfactory because of shared antigenicity between normal and malignant T cells, resulting in fratricide and hindering CAR production...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Jing, Jia, Yujie, Tuhin, Israth Jahan, Tan, Jingwen, Monty, Masuma Akter, Xu, Nan, Kang, Liqing, Li, Minghao, Lou, Xiaoyan, Zhou, Meixia, Fang, Xiaoyan, Shao, Jiaqi, Zhu, Hongjia, Yan, Zhiqiang, Yu, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913247/ https://www.ncbi.nlm.nih.gov/pubmed/35317521 http://dx.doi.org/10.1016/j.omto.2022.02.013

Ejemplares similares

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
por: Tan, Jingwen, et al.
Publicado: (2022)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
por: Luo, Zhiqiang, et al.
Publicado: (2023)

Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19
por: Wen, Hairuo, et al.
Publicado: (2021)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
por: Atilla, Pinar Ataca, et al.
Publicado: (2022)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
por: Ambrose, Christine, et al.
Publicado: (2021)

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
por: Gill, Saar, et al.
Publicado: (2022)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems
por: Krebs, Simon K., et al.
Publicado: (2022)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
por: Blaeschke, Franziska, et al.
Publicado: (2022)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022)

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma
por: Kang, Liqing, et al.
Publicado: (2020)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer
por: Klapdor, Rüdiger, et al.
Publicado: (2019)

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
por: Feng, Jia, et al.
Publicado: (2021)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
por: Caimi, Paolo F., et al.
Publicado: (2021)

COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
por: Panagiota, Victoria, et al.
Publicado: (2023)

Design and preclinical testing of an anti‐CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
por: Tigu, Adrian Bogdan, et al.
Publicado: (2023)

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
por: Kim, Miriam Y., et al.
Publicado: (2021)

The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
por: Leung, Joanne, et al.
Publicado: (2014)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
por: Rotolo, Antonia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0alpebvcgndqpo7ck9f27c2nm4